In comparison to the RECIST 1.1 criteria, use of the mpMRI-based NacBI-RADS system for evaluating response to neoadjuvant chemotherapy (NAC) for breast cancer offered an 8 percent higher sensitivity and over 26 percent higher specificity.
In a new podcast episode, Manisha Bahl, MD, MPH, FSBI, discusses recently published guidelines on proliferative breast lesions with atypia and lobular carcinoma in situ (LCIS).
In a new podcast episode, Thomas Hope, MD, shares his insights on glioma imaging and the potential impact of the recently FDA-approved PET agent floretyrosine (18F-FET),
In a new webinar program, Raj Chopra, MD and Peter Reilly share their insights on the importance of cybersecurity, keys to effective downtime communication, the ripple effects and costs of security breaches, challenges with AI and practical safeguards.